Abstract
Mycobacterium bovis infection after intravesical Bacillus Calmette-Guérin (BCG) therapy is rare. A 65-year-old Japanese man with history of bladder cancer and intravesical BCG therapy, presented with low-grade fever. An aneurysm with perianeurysmal fluid was suspected and endovascular aortic repair was performed. After 160 days, he developed blood-streaked sputum and computed tomography images revealed that the perianeurysmal fluid area was increasing in size. A multiplex polymerase chain reaction using sputum identified M. bovis. Treatment with anti-tuberculosis drugs reduced the size of the perianeurysmal fluid area. After intravesical BCG therapy, the possibility of M. bovis infection should be considered, thus further investigations are required.
Keywords: Mycobacterium bovis, aortic aneurysm, Bacillus Calmette-Guérin therapy, multiplex polymerase chain reaction
Introduction
Bacillus Calmette-Guérin (BCG) intravesical therapy is widely used for the treatment of superficial bladder cancer. The exact mechanisms underlying the antitumor effects of BCG are unknown. The intravesical instillation of BCG triggers a variety of local immune responses that may persist for a number of months and which appear to be correlated with antitumor activity (1, 2). Its efficacy as an immunotherapy drug has been demonstrated in the treatment of bladder cancer and as prophylaxis against local recurrence (3). In 2006, it was estimated that there were 16,510 cases of bladder cancer in Japan; approximately 70% of untreated cases of bladder cancer involved non-muscular invasive bladder cancer, for which BCG therapy might have been appropriate (4). Intravesical BCG instillation is generally considered safe. Lamm et al., reported that the most common complications of intravesical BCG instillation are high fever (2.9%), hematuria (1%), and infectious granulomatous complications, such as hepatitis (0.5%) and pneumonia (0.5%) (5). However, some cases of life threatening BCG sepsis have been reported (5). Mycobacterium bovis infection of an aortic aneurysm after intravesical BCG therapy is an extremely rare complication. In this report, we document the case of a 65-year-old man who developed a ruptured aortic aneurysm due to M. bovis infection after intravesical BCG therapy.
Case Report
A 65-year-old Japanese man was admitted to a different institution with low-grade fever, which had persisted for 31 days, 13 days before his admission to our hospital. He did not have any other symptoms, and chest radiography and abdominal computed tomography (CT) images were not suggestive of any abnormal findings. However, chest CT images revealed a thoracic saccular aneurysm with perianeurysmal fluid. No evidence of the aneurysm was found on CT images taken 11 months earlier. Since the possibility of an infected aneurysm could not be denied based on the CT findings or the patient's symptoms, ampicillin/sulbactam (ABPC/SBT) was administered at a conventional dose of 3 grams every 6 hours [10 days before admission, ABPC/SBT was replaced by meropenem (1 gram every 6 hours)]. Two sets of blood cultures were obtained before antibiotic treatment was initiated; both returned negative results. Twelve days after the initiation of antibiotics, the patient complained of sudden back pain and progressed to hypovolemic shock. Repeat CT images revealed a ruptured thoracic aortic aneurysm, measuring 2.5×1.9 cm, with pleural effusion that indicated hemothorax (Fig. 1). He was therefore transferred to our hospital.
Figure 1.
Chest radiography and computed tomography images obtained on the day of admission to our hospital. (A) Chest radiography shows left pleural effusion. (B) Chest computed tomography images reveal a ruptured thoracic aortic aneurysm (white arrow), measuring 2.5×1.9 cm, with pleural effusion that suggested hemothorax.
Upon admission, a physical examination revealed the following: body temperature, 36.2℃; blood pressure, 74/52 mmHg; heart rate, 78 beats/min; regular respiratory rate, 24 breaths/min. Respiratory tract sounds were not audible in the left lung. He had no peripheral lymphadenopathy, skin lesions, or neurological deficits, and cardiovascular and the abdominal examinations were unremarkable. His laboratory findings were as follows: white blood cells, 4,930 /μL; hemoglobin, 5.9 g/dL; platelets, 5.5×104/μL; C-reactive protein, 1.45 mg/dL; serum total protein, 5.3 g/dL; albumin, 3.5 g/dL; lactate dehydrogenase, 138 IU/L; aspartate aminotransferase, 123 IU/L; alanine aminotransferase, 33 IU/L; gamma-glutamyltransferase, 18 IU/L; blood urea nitrogen, 14 mg/dL; and creatinine, 0.65 mg/dL. An interferon-gamma release assay (T-SPOT.TB™) yielded a negative result.
We revisited the patient's history of bladder cancer. He had received six courses of intravesical BCG therapy [BCG Tokyo 172; BCG (80 mg) was injected through a catheter into the patient's bladder every week for 6 weeks] 12 months previously. He had fever immediately after his sixth course of BCG. Based on his medical history, we performed culturing and polymerase chain reactions (PCRs) using blood, urine, pleural effusion, and bone marrow aspiration specimens, in order to test for Mycobacterium tuberculosis (M. tuberculosis) complex; however, these tests yielded negative results. Blood was cultured for M. tuberculosis complex with a method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride (STC).
In view of his medical problems, open surgery was considered too risky. He was therefore treated with thoracic endovascular aortic repair and gauze packing in the left intrathoracic space. If his condition worsened, anti-tuberculosis treatment would have been administered. However, his condition improved following the initiation of treatment, and the antibiotics that were administered by the previous institution, were discontinued at 10 days after admission because the patient's blood and pleural effusion bacterial cultures were negative. Sixty-one days after admission, gauze removal surgery was performed, and the patient was discharged on the 83rd day after admission. During admission, he developed thrombocytopenia and was diagnosed with idiopathic thrombocytopenic purpura. Oral prednisone was initiated at a total daily dose of 60 mg and his overall condition appeared to stabilize over the 5 months that followed, leading to the discontinuation of the medication.
One hundred sixty days after admission, he developed blood-streaked sputum. His sputum was tested for M. tuberculosis using acid-fast staining and a PCR; both tests were positive. The isolate identified as M. tuberculosis complex was examined using a multiplex PCR analysis of the cfp32 gene and regions of difference 1, 9, 12, and 16. The methods employed by Chikamatsu et al. were used and in doing so the investigators identified BCG Tokyo172 (6) (Fig. 2). Conclusively, the acid-fast bacilli culture of the sputum grew M. bovis. The minimum inhibitory concentrations (MICs) of the anti-microbial agents against M. bovis was determined using BrothMIC MTB-I (Kyokuto Pharmaceutical Industrial, Tokyo, Japan) and the KYOKUTO PZA test, was as follows: rifampicin, ≤0.031 mg/L; isoniazid, 0.125 mg/L; etambutol, 1.0 mg/L; levofloxacin, 0.5 mg/L. However, the M. bovis was resistant to pyrazinamide. Chest radiography and CT images revealed neither infiltrative changes nor nodules; however, the low attenuation area surrounding the aortic graft was increasing in size and there adhesion to the left lower lobe of the lung was suspected (Fig. 3). Anti-tuberculosis treatment with rifampicin (600 mg, once daily), isoniazid (300 mg, once daily) and etambutol (750 mg, once daily) resulted in the resolution of the patient's symptoms and follow-up chest CT performed 6 months after the development of blood-streaked sputum showed a decrease in the size of the low attenuation mass surrounding the aortic graft.
Figure 2.
The multiplex polymerase chain reaction to test for Mycobacterium bovis (M. bovis) (M: marker, ①, ②: the patient sample isolated from sputum, ③: Non-tuberculosis mycobacterium, ④: Bacillus Calmette-Guérin (BCG) Tokyo 172, ⑤: Mycobacterium tuberculosis (M. tuberculosis), ⑥: Negative control). (A) The isolates identified as M. bovis or Mycobacterium caprae by a multiplex polymerase chain reaction of cfp32 and region of difference 9 and 12. (B) The isolates identified as BCG by a polymerase chain reaction of region of difference 1 (region of difference 1: BCG: 200 bp, other M. tuberculosis complex: 150 bp). (C) The isolates were identified as BCG Tokyo 172 by region of difference 16 (the size of region of difference 16 in BCG Tokyo 172 is unique).
Figure 3.
The clinical course. These images revealed that the low attenuation mass surrounding the aortic graft was increasing (white arrows) with time. The gauze in the intrathoracic space is represented by a white circle. ABPC/SBT: ampicillin/sulbactam, EB: etambutol, INH: isoniazid, RFP: rifampicin
Discussion
Infected aortic aneurysms are a rare form of aneurysm (0.9-1.3%) but result in serious clinical conditions and high mortality (7, 8). The most common causative pathogen is Staphylococcus aureus,followed by Streptococcus spp., Salmonella, and Escherichia coli (9). M. bovis includes several mycobacteria of the M. tuberculosis complex, which are closely related and pathogenic. It has a wide range of wild and domestic animal hosts; in the United States during 2006-2013, it caused 1.3-1.6% of culture-confirmed cases of tuberculosis in humans (10). BCG was recommended as a vaccine for tuberculosis and bladder cancer, following the evaluation of its efficacy and safety in clinical trials conducted in France in 1921. However, BCG-related infectious complications may occur following vaccination and intravesical BCG therapy. To our knowledge, in addition to our patient, the literature contains reports on a total of 29 patients with aneurysms infected by M. bovis after intravesical BCG therapy (11-36) (Table). According to these reports, all of the cases occurred in adults [mean age±standard deviation (SD): 71.1±5.46 years], and 28 of the 29 patients were males. The median time interval (±SD) between the last instillation and the onset of infection was 17 months (±15.9). Among the 21 patients who were reported to have complications when BCG was administered, fever was observed in 14 (66.6%); this frequency was higher than that reported in a review of 2,602 (2.9%) patients who were treated with intravesical BCG (5). Among the 29 patients with M. bovis-infected aneurysms, 22 (75.9%) exhibited underlying disease, 6 (27.3%) had at least one risk factor for arterial sclerosis [hypertension (n=5), diabetes mellitus (n=2), and dyslipidemia (n=2)], 12 (54.5%) had a history of coronary artery disease or aneurysm, and 6 (27.3%) had a history of smoking. All patients exhibited at least one symptom; fever was observed in 14 (48.3%) patients while pain was observed in 23 (79.3%) patients. Lee et al., reported that the imaging features of infected aneurysms included lobulated vascular masses, indistinct, irregular arterial walls, perianeurysmal edema, and perianeurysmal soft-tissue masses (37). However, it was difficult to distinguish atherosclerotic aneurysms in some patients.
Table.
Twenty Nine Reported Cases of Infected Aneurysm by Mycobacterium Bovis.
| Case | Sex | Age | Main underlying diseases excluding bladder cancer | The complication caused by BCG injection | Location | Interval*(month) | Main symptoms | The method of diagnosis (infection by BCG) | Outcome | References |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | W | 62 | Malignant melanoma | Bacteremia | Infrarenal aorta | 17 | Back pain | Culture of aneurysm specimen | Recovered | 10 |
| 2 | M | 74 | Unknown | Fever and pain localized at the bladder | Femoral artery | 21 | lumbar pain | Culture of pelvic collection and thrombus | Recovered | 11 |
| 3 | M | 67 | None | Fever, hypotension and anuria | Abdominal aorta, iliac artery | 14 | Fever, dysuria, and dull | Pathology of autopsy specimen | Died | 12 |
| 4 | M | 69 | Aneurysm | Mild urgency and frequency of urination | Aortic arch | 36 | Confusion, weight loss, and fatigue | Culture of autopsy specimen | Died | 13 |
| 5 | M | 80 | Unknown | Fever and rigors | Infrarenal aorta | 24 | Back pain | Culture of fluid surrounding aortic graft | Recovered | 14 |
| 6 | M | 71 | Aneurysm | Malaise | Abdominal aorta | 26 | Fever and malaise | Culture of aneurysm specimen | Recovered | 15 |
| 7 | M | 76 | Myocardial infarction | Unknown | Infrarenal aorta | 77 | Back and leg pain, and weight loss | Needle biopsy sampling culture of vertebral disk | Died | 16 |
| 8 | M | 71 | Myocardial infarction and atrial fibrillation | Dysuria | Infrarenal aorta | 7 | Abdominal pain and fever | Bacteriological analysis of aneurysm | Recovered | 17 |
| 9 | M | 75 | Coronary artery disease | Unknown | Infrarenal aorta | 8 | Back pain | Needle biopsy sampling culture of the iliopsoas muscle | Recovered | 18 |
| 10 | M | 72 | Deep venous thrombosis | Sweating and flu-like symptoms | Femoral artery | 12 | Fever and inguinal pain | Culture of sputum and tissue of aneurysm | Recovered | 19 |
| 11 | M | 58 | Unknown | Unknown | Abdominal aorta | 36 | Fever, back pain and weight loss | Culture of aneurysm specimen | Recovered | 19 |
| 12 | M | 71 | Aneurysm | Malaise | Infrarenal aorta | 48 | Fever | Culture of aneurysm specimen | Recovered | 19 |
| 13 | M | 74 | Coronary artery disease, hypertension, and diverticulosis | Confusion, chills, fever, pancytopenia, and transaminitis | Infrarenal aorta | 12 | Weakness, diaphoresis and dyspnea | Culture of aneurysm specimen | Recovered | 20 |
| 14 | M | 68 | Unknown | Fever and malaise | Carotid artery | 24 | Neck swelling | Needle biopsy sampling culture of lymph node | Recovered | 21 |
| 15 | M | 65 | Aneurysm | None | Suprarenal aorta | 16 | Abdominal pain, nausea and weight loss | Culture of autopsy specimen | Died | 22 |
| 16 | M | 75 | Unknown | Fever | Infratenal aorta and femoral artery | 32 | Pain in the hip joint | Culture of aneurysm specimen | Recovered | 23 |
| 17 | M | 67 | Unknown | Fever and malaise | Popliteal artery | 23 | Fever and pain in the knee | Clinical diagnosis | Recovered | 24 |
| 18 | M | 69 | Appendicitis, colon cancer, and aneurysm | Unknown | Infrarenal aorta | 48 | Back pain and paresis | Culture of surgical bone sampling | Recovered | 25 |
| 19 | M | 80 | Hypertension and chronic obstructive pulmonary disease | Malaise | Infrarenal aorta | 24 | Fever, malaise, weight loss and back pain | Culture of aneurysm specimen | Recovered | 26 |
| 20 | M | 79 | Coronary artery disease | Unknown | Infrarenal aorta | 11 | Fever, fatigue and nigh sweat | Culture of aneurysm specimen | Recovered | 27 |
| 21 | M | 75 | Hypertension, diabetes, and dyslipidemia | Urosepsis | Abdominal aorta and femoral artery | 24 | Abdominal and back pain | Culture of blood and tissue of aneurysm | Recovered | 28 |
| 22 | M | 79 | None | Unknown | Carotid artery etc | 18 | Neck pain, fatigue and weight loss | Culture of abscess surrounding aneurysm | Died | 29 |
| 23 | M | 75 | Hypertension, lymphoma, dyslipidemia, and chronic kidney disease | Fever, lethargy, and headaches | Suprarenal aorta | 15 | Fever, dyspnea, weight loss | Clinical diagnosis | Died | 30 |
| 24 | M | 69 | Coronary artery disease, hypertension, and atrial fibrillation | Unknown | Infrarenal aorta | 10 | Fever and back pain | Pathology of aneurysm specimen | Recovered | 31 |
| 25 | M | 64 | Coronary artery disease and diabetes | Fever | Infrarenal aorta and iliac artery | 9 | Fever and abdominal pain | Culture of pelvic retroperitoneal collection | Recovered | 32 |
| 26 | M | 68 | Gastric cancer | Fever | Infrarenal aorta | 7 | Back pain | Culture of aneurysm specimen | Recovered | 33 |
| 27 | M | 73 | None | Fever | Thoracic and abdominar aorta | 10 | Abdominal pain | Culture of aneurysm specimen and abscess of psoas muscle | Recovered | 34 |
| 28 | M | 70 | Unknown | Unknown | Abdominal aorta, iliac artery | 1 | Fever and back pain | Culture of aneurysm specimen | Recovered | 35 |
| 29 | M | 65 | None | Fever | Thoracic aorta | 10 | Fever and back pain | Culture of sputum | Recovered | Present case |
BCG: Bacillus Calmette-Guérin
*The interval: the time interval between the last instillation and the onset of infection
Long et al. reported that tubercle bacilli may reach the aortic wall in one of three ways: the direct bacterial invasion of the arterial wall with degeneration due to atherosclerosis; the invasion of the adventitia or media by the vasa vasorum; or direct extension from a contiguous focus such as a lymph node or paraspinal abscess (38). Among the patients that are listed in Table, the methods that were used to diagnose M. bovis-induced aneurysms included the culture of the aneurysm (n=16), the culture of the tissue surrounding the aneurysm (n=7), a clinical diagnosis (n=5), [the culture of another tissue type (n=1), the pathological examination of the aneurysm (n=2), and other (n=2)]. In the present case, open surgery was considered to be associated with a high degree of risk. For this reason, histopathological and microbiological examinations were not performed to confirm the diagnosis. Thus, the M. bovis-induced aneurysm was clinically diagnosed using the following evidence: the rapid formation of a thoracic saccular aneurysm with perianeurysmal fluid in only 11 months; the increased size of the low attenuation area surrounding the aortic grafts within 160 days; the decrease in the area of the perianeurysmal fluid after treatment with anti-tuberculosis drugs. M. bovis isolated from sputum was possibly derived from the area of low attenuation surrounding the aortic graft, since the CT images revealed that only the perianeurysmal fluid area adhered to the left lower lobe of the lung and that neither infiltrative changes nor nodules were observed. In addition, oral prednisone might have contributed to the deterioration of the infected aneurysm, thus masking fever. Moreover, the gauze removal surgery might have worsened the perianeurysmal infection. The blood-streaked sputum eventually resolved and the low attenuation mass surrounding the aortic graft decreased in size after treatment with anti-tuberculosis drugs.
The treatment of aortic aneurysms due to M. bovis include antimicrobial therapy with or without surgery. M. bovis is usually susceptible to anti-tuberculosis drugs, including rifampicin, isoniazid, and etambutol. It is resistant to pyrazinamide (39). However, the optimal duration of therapy for aortic aneurysms is unknown. Thirteen of the cases of aortic aneurysms that we reviewed included data on the duration of antimicrobial therapy after the diagnosis; 12 cases received antibiotic treatment for ≥9 weeks and 9 cases received antibiotic treatment for ≥12 weeks. Moreover, in some cases, medical therapy alone was inadequate (15, 21). The surgical managements included debridement of the vessel with extra-anatomic bypass and in situ repair with a prosthetic graft; both methods have yielded good results. In the present case, open surgery was considered to be too risky; thus, he was treated using thoracic endovascular aortic repair. Ting et al. reported that a patient with multiple Salmonella infected thoracic aortic aneurysms, was successfully treated by endovascular repair (40). However, in the presence of infection, this technique should therefore be considered on an individual basis.
In conclusion, we described a case of a ruptured aortic aneurysm caused by M. bovis, which was challenging to diagnose. In some cases after intravesical BCG therapy, we should consider the possibility of aneurysm caused by M. bovis and it may be important to conduct further evaluations, including surgical and microbiological evaluations.
The authors state that they have no Conflict of Interest (COI).
References
- 1. Prescott S, Jackson AM, Hawkard SJ, Alecandroff AB, James K. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis 3: S91-S93, 2000. [DOI] [PubMed] [Google Scholar]
- 2. Bohle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170: 964-969, 2003. [DOI] [PubMed] [Google Scholar]
- 3. Patard J, Moudouni S, Saint F, et al. Tumor progression and survival in patients with T1 G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years. Urology 58: 551-556, 2001. [DOI] [PubMed] [Google Scholar]
- 4. Matsuda T, Marugame T, Kamo K, Katanoba K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2006: based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 42: 139-147, 2012. [DOI] [PubMed] [Google Scholar]
- 5. Lamm DL, van der Meijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guérin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992. [DOI] [PubMed] [Google Scholar]
- 6. Chikamatsu K, Aono A, Yamada H, et al. Comparative evaluation of three immunochromatographic identification tests for culture confirmation of Mycobacterium tuberculosis complex. BMC infect Dis 14: 54, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Muller BT, Wegener OR, Grabitz K, Pillny M, Thomas L, Sandmann W. Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg 33: 106-113, 2001. [DOI] [PubMed] [Google Scholar]
- 8. Chan FY, Crawford ES, Coselli JS, Safi HJ, Williams TW Jr. In situ prosthetic graft replacement for mycotic aneurysm of the aorta. Ann Thorac Surg 47: 193-203, 1989. [DOI] [PubMed] [Google Scholar]
- 9. Miller DV, Oderich GS, Aubry MC, Panneton JM, Edwards WD. Surgical pathology of infected aneurysms of the descending thoracic and abdominal aorta: clinicopathologic correlations in 29 cases (1976 to 1999). Hum Pathol 35: 1112-1120, 2004. [DOI] [PubMed] [Google Scholar]
- 10. Scott C, Cavanaugh JS, Pratt R, Silk BJ, LoBue P, Moonan PK. Human tuberculosis caused by Mycobacterium bovis in the United States, 2006-2013. Clin Infect Dis 63: 594-601, 2016. [DOI] [PubMed] [Google Scholar]
- 11. Woods JM 4th, Schellack J, Stewart MT, Murray DR, Schwartzman SW. Mycotic abdominal aortic aneurysm induced by immunotherapy with bacille Calmette-Guérin vaccine for malignancy. J Vasc Surg 7: 808-810, 1988. [DOI] [PubMed] [Google Scholar]
- 12. Bornet P, Pujade B, Lacaine F, et al. Tuberculous aneurysm of the femoral artery: a complication of bacille Calmette-Guérin vaccine immunotherapy--a case report. J Vasc Surg 10: 688-692, 1989. [PubMed] [Google Scholar]
- 13. Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 144: 1331-1333, 1990. [DOI] [PubMed] [Google Scholar]
- 14. Izes JK, Bihrle W, Thomas CB. Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol 150: 1498-1500, 1993. [DOI] [PubMed] [Google Scholar]
- 15. Wolf YG, Wolf DG, Higginbottom PA, Dilley RB. Infection of a ruptured aortic aneurysm and an aortic graft with bacille Calmette-Guérin after intravesical administration for bladder cancer. J Vasc Surg 22: 80-84, 1995. [DOI] [PubMed] [Google Scholar]
- 16. Hellinger WC, Oldenburg WA, Alvarez S. Vascular and other serious infections with Mycobacterium bovis after bacillus of Calmette-Guérin therapy for bladder cancer. South Med J 88: 1212-1216, 1995. [DOI] [PubMed] [Google Scholar]
- 17. Rozenblit A, Wasserman E, Marin ML, Veith FJ, Cynamon J, Rozenblit G. Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guérin therapy. AJR Am J Roentgenol 167: 711-713, 1996. [DOI] [PubMed] [Google Scholar]
- 18. Damm O, Briheim G, Hagstrom T, Jonsson B, Skau T. Ruptured mycotic aneurysm of the abdominal aorta: a serious complication of intravesical instillation bacillus Calmette-Guerin therapy. J Urol 159: 984, 1998. [DOI] [PubMed] [Google Scholar]
- 19. LaBerge JM, Kerlan RK Jr, Reilly LM, Chuter TA. Diagnosis please. Case 9: mycotic pseudoaneurysm of the abdominal aorta in association with mycobacterial psoas abscess--a complication of BCG therapy. Radiology 211: 81-85, 1999. [DOI] [PubMed] [Google Scholar]
- 20. Seelig MH, Oldenburg WA, Klingler PJ, Blute ML, Pairolero PC. Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. J Vasc Surg 29: 377-381, 1999. [DOI] [PubMed] [Google Scholar]
- 21. Farber A, Grigoryants V, Palac DM, Chapman T, Cronenwett JL, Powell RJ. Primary aortoduodenal fistula in a patient with a history of intravesical therapy for bladder cancer with bacillus Calmette-Guérin: review of primary aortoduodenal fistula without abdominal aortic aneurysm. J Vasc Surg 33: 868-873, 2001. [DOI] [PubMed] [Google Scholar]
- 22. Geldmacher H, Taube C, Markert U, Kirsten DK. Nearly fatal complications of cervical lymphadenitis following BCG immunotherapy for superficial bladder cancer. Respiration 68: 420-421, 2001. [DOI] [PubMed] [Google Scholar]
- 23. Kamphuis JT, Buiting AG, Misere JF, van Berge Henegouwen DP, van Soolingen D, Rensma PL. BCG immunotherapy: be cautious of granulomas. Disseminated BCG infection and mycotic aneurysm as late complications of intravesical BCG instillations Neth J Med 58: 71-75, 2001. [DOI] [PubMed] [Google Scholar]
- 24. Wada S, Watanabe Y, Shiono N, et al. Tuberculous abdominal aortic pseudoaneurysm penetrating the left psoas muscle after BCG therapy for bladder cancer. Cardiovasc Surg 11: 231-235, 2003. [DOI] [PubMed] [Google Scholar]
- 25. Witjes JA, Vriesema JL, Brinkman K, Bootsma G, Barentsz JO. Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Urol Int 71: 430-432, 2003. [DOI] [PubMed] [Google Scholar]
- 26. Dahl T, Lange C, Ødegård A, Bergh K, Osen SS, Myhre HO. Ruptured abdominal aortic aneurysm secondary to tuberculous spondylitis. Int Angiol 24: 98-101, 2005. [PubMed] [Google Scholar]
- 27. Harding GE, Lawlor DK. Ruptured mycotic abdominal aneurysm secondary to Mycobacterium bovis after intravesical treatment with bacillus Calmette-Guérin. J Vasc Surg 46: 131-134, 2007. [DOI] [PubMed] [Google Scholar]
- 28. Safdar N, Abad CL, Kaul DR, Jarrard D, Saint S. Clinical problem-solving. An unintended consequence--a 79-year-old man with a 5-month history of fatigue and 20-Ib (9-kg) weight loss presented to his local physician. N Engl J Med 358: 1496-1501, 2008. [DOI] [PubMed] [Google Scholar]
- 29. Costiniuk CT, Sharapov AA, Rose GW, et al. Mycobacterium bovis abdominal aortic and femoral artery aneurysms following intravesical bacillus Calmette-Guérin therapy for bladder cancer. Cardiovasc Pathol 19: e29-e32, 2010. [DOI] [PubMed] [Google Scholar]
- 30. Coscas R, Arlet JB, Belhomme D, Fabiani JN, Pouchot J. Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy. J Vasc Surg 50: 1185-1190, 2009. [DOI] [PubMed] [Google Scholar]
- 31. Maundrell J, Fletcher S, Roberts P, Stein A, Lambie M. Mycotic aneurysm of the aorta as a complication of Bacillus Calmette-Guérin instillation. J R Coll Physicians Edinb 41: 114-116, 2011. [DOI] [PubMed] [Google Scholar]
- 32. Orii K, Honda J, Hirai Y. Tuberculous abdominal aortic aneurysm after intravesical bacillus Calmette-Guérin therapy. Jpn J Vasc Surg 21: 803-808, 2012(in Japanese, Abstract in English). [Google Scholar]
- 33. Kioka Y, Tanabe A, Kuriyama M. A case report of mycotic aneurysm following intravasical bacillus Calmette-Guérin instillation therapy for bladder cancer. Jpn J Cardiovasc Surg 41: 312-315, 2012(in Japanese, Abstract in English). [Google Scholar]
- 34. Asami F, Yamaguchi H, Nakao T, et al. A pseudoaneurysm of abdominal aorta-after intravasical bacillus Calmette-Guérin therapy. Jpn J Cardiovasc Surg 42: 197-199, 2013(in Japanese, Abstract in English). [Google Scholar]
- 35. Fujii K, Mizumoto T, Shomura Y, Fujinaga K, Sawada Y. A case of tuberculous multiple aortic aneurysm after intravesical bacillus Calmette-Guérin therapy. Jpn J Vasc Surg 24: 822-826, 2015(in Japanese, Abstract in English). [Google Scholar]
- 36. Nam EY, Na SH, Kim SY, et al. Infected aortic aneurysm caused by Mycobacterium bovis after intravesical Bacillus Calmette-Guérin treatment for bladder cancer. Infect Chemother 47: 256-260, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Lee WK, Mossop PJ, Little AF, et al. Infected (mycotic) aneurysms: spectrum of imaging appearances and management. Radiographics 28: 1853-1868, 2008. [DOI] [PubMed] [Google Scholar]
- 38. Long R, Guzman R, Greenberg H, Safneck J, Hershfield E. Tuberculous mycotic aneurysm of the aorta: review of published medical and surgical experience. Chest 115: 523-531, 1999. [DOI] [PubMed] [Google Scholar]
- 39. Lamm DL, van der Maijden PM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147: 596-600, 1992. [DOI] [PubMed] [Google Scholar]
- 40. Ting AC, Cheng SW, Ho P, Poon JT. Endovascular repair for multiple Salmonella mycotic aneurysms of the thoracic aorta presenting with Cardiovocal syndrome. Eur J Cardiothorac Surg 26: 221-224, 2004. [DOI] [PubMed] [Google Scholar]



